Despite survival improvements achieved over the last two decades, prostate cancer remains
lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches …

Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically
actionable aberrations across numerous cancer types in real-time. With the development of …

No consensus strategies exist for prognosticating metastatic castration-resistant prostate
cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by …

Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …

De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely
collected tissue has hindered genomic stratification and precision oncology. Here, we …

Growing bodies of evidence have demonstrated that the identification of prostate cancer
(PCa) biomarkers in the patients' blood and urine may remarkably improve PCa diagnosis …

In a large number of cancer types, treatment selection depends on the presence of specific
tumor biomarkers. Due to the dynamic nature of cancer, very often these predictive …

Metastatic prostate cancer remains a major clinical challenge and metastatic lesions are
highly heterogeneous and difficult to biopsy. Liquid biopsy provides opportunities to gain …

Simple Summary ctDNA is a small DNA fragment derived from tumor cells, which contains
tumor-related genomic information, such as mutation, methylation, microsatellite instability …

Purpose: Cross-resistance renders multiple lines of androgen receptor (AR) signaling
inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We …